Related references
Note: Only part of the references are listed.Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report
Magnus Fall et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2020)
Phenotypic and Functional Diversity of Mast Cells
Satoshi Tanaka
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Novel reactivation and degranulation of mast cells
Liao Huanjin et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis
Melanie C. Dispenza et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Pathophysiology of interstitial cystitis
Lori A. Birder
INTERNATIONAL JOURNAL OF UROLOGY (2019)
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
Susanne Gamperl et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2019)
Future Needs in Mast Cell Biology
Gilda Varricchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
GAG replenishment therapy for bladder pain syndrome/interstitial cystitis
Jean Jacques J. Wyndaele et al.
NEUROUROLOGY AND URODYNAMICS (2019)
Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity
Stefania Petrosino et al.
JOURNAL OF NEUROINFLAMMATION (2019)
IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model
M. Martin Jensen et al.
CYTOKINE (2018)
Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies?
Shabana T. Malik et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells
Carolin N. Zorn et al.
SCIENTIFIC REPORTS (2018)
Investigational drugs for bladder pain syndrome (BPS)/interstitial cystitis (IC)
Yao-Chi Chuang et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Peter Norman
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide
Weishan Huang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Novel agents in the treatment of multiple myeloma: a review about the future
Leonard Naymagon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline Amendment
Philip M. Hanno et al.
JOURNAL OF UROLOGY (2015)
Intravesical treatments of bladder pain syndrome/interstitial cystitis
Jochen Neuhaus et al.
NATURE REVIEWS UROLOGY (2012)
Co-morbidities of interstitial cystitis
Gisela Chelimsky et al.
FRONTIERS IN NEUROSCIENCE (2012)
Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells
Hye Sun Kuehn et al.
JOURNAL OF CELL SCIENCE (2010)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal
Joop P. van de Merwe et al.
EUROPEAN UROLOGY (2008)
The mast cell in interstitial cystitis: Role in pathophysiology and pathogenesis
Grannum R. Sant et al.
UROLOGY (2007)
Highlights from the combined Society of Urodynamics and Female Urology, and International Society of pelvic neuromodulation annual meeting
Gary E. Lemack et al.
JOURNAL OF UROLOGY (2007)
Share Paper
